Concepedia
Statistics
Publications
5
Citations
124
H-Index
Active since
2005
Affiliations
Seagen (United States)(Current)
Bristol-Myers Squibb (United States)
Merck & Co., Inc., Rahway, NJ, USA (United States)
Srinath Thirumalairajan is an author at Seagen (United States) specializing in pharmacy, medicinal chemistry, and pharmaceutics.
Publications per year
2005–2023
The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase
T. Heikkila, Srinath Thirumalairajan, Matthew Davies et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 63 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +8
Rational design and synthesis of substrate–product analogue inhibitors of α-methylacyl-coenzyme A racemase from Mycobacterium tuberculosis
Mohan Pal, Mandar Khanal, Ryan Marko et al. · Chemical Communications · 2015 · 20 citations
Pharmacy, Chemical Biology, Medicinal Chemistry +17
Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices
Paul G. Bulger, David A. Conlon, Russell D. Cink et al. · Organic Process Research & Development · 2023 · 15 citations
Pharmacy, Medicinal Chemistry, Pharmaceutics +17
Development of a Single-Step Antibody–Drug Conjugate Purification Process with Membrane Chromatography
Juan Carlos Cordova, Sheng Sun, Jeffrey Bos et al. · Journal of Clinical Medicine · 2021 · 14 citations · Full text
Pharmacy, Pharmaceutical Biotechnology, Pharmaceutics +17
Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates
Lara Fernandez‐Cerezo, Melissa Holstein, Srinath Thirumalairajan et al. · Organic Process Research & Development · 2023 · 12 citations
1–5 of 5